{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-017211","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.838699+00:00","generated_at":"2026-05-21T04:36:31.881996+00:00","sec_items":["1.01","2.02","2.03","3.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%","bullets":["Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.","Cash and short-term investments $52.4M at Mar 31, 2025, down $37.7M from Dec 31, 2024.","Exchanged $70.8M of 5.25% 2026 notes for new 9.50% 2029 notes; additionally $10M notes converting to equity.","Outstanding 2026 notes reduced to ~$17.1M; avoids $20M term loan prepayment plus $1M premium due Nov 2025.","FDA accepted BLA for narsoplimab in TA-TMA; PDUFA date Sep 25, 2025. Phase 3 PNH program paused to conserve cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-017211","json":"https://secwatch.observer/filing/0001437749-25-017211.json","markdown":"https://secwatch.observer/filing/0001437749-25-017211.md","text":"https://secwatch.observer/filing/0001437749-25-017211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/0001437749-25-017211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/omer20250407_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:36:31.881996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}